Big biotech, Biotech, Drug delivery, M&A, Pharma

M&A news: Acorda has purchased Civitas Therapeutics

Posted on 25 September 2014

Tags: , , , ,

In today's M&A news, Acorda Therapeutics announced that it will acquire Civitas Therapeutics for $525 million in cash.

Acorda will acquire CVT-301, a Phase 3 candidate for Parkinson’s disease and the rights to ARCUS, Civitas’s pulmonary delivery technology, and a manufacturing facility in Chelsea, Mass.

CVT-301 is a dry powder L-dopa formulation in blister-packed capsules and delivered with a proprietary reusable inhaler. The therapeutics for treatment of OFF episodes of Parkinson’s is expected to begin in early 2014.

If successful, the company plans to submit regulatory filings in the U.S. by the end of 2016.

For further deal information visit Current Agreements (subscription required)


Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Pharma and Biotech M&A Trends 2009-2014

Browse: Complete Current Partnering report catalog

View: M&A Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply